LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open.
RNS Number : 4032O Renalytix PLC 08 October 2021 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21 LONDON and SALT LAKE CITY , October 8, 2021 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced
Jed Fulk Appointed Vice President Sales, Government Accounts NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration
RNS Number : 2788O Renalytix PLC 07 October 2021 Renalytix plc (" Renalytix " or the " Company ") Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals Jed Fulk Appointed Vice President Sales, Government Accounts NEW YORK and SALT LAKE CITY , October 7, 2021 -
RNS Number : 0377M Renalytix PLC 16 September 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 8680L Renalytix PLC 15 September 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 8670L Renalytix PLC 15 September 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
RNS Number : 7773L Renalytix PLC 14 September 2021 This announcement contains inside information Renalytix plc (" Renalytix " or the " Company ") Update on MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics NEW YORK , September 14, 2021 - Renalytix
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™
RNS Number : 6348L Renalytix PLC 14 September 2021 This announcement contains inside information Renalytix plc (" Renalytix " or the " Company ") Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX TM Enabled Health Care Model Targeted testing run rate of 300 diabetic
